Ryvu Therapeutics S.A. (FRA:9Y4)
Germany flag Germany · Delayed Price · Currency is EUR
6.07
-0.19 (-3.04%)
At close: Jan 30, 2026

Ryvu Therapeutics Ratios and Metrics

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jan '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
142208306243244198
Market Cap Growth
-18.71%-32.00%25.72%-0.33%23.52%16.92%
Enterprise Value
132169249235226163
Last Close Price
6.078.8113.4810.3813.14-
PS Ratio
6.708.7319.7616.6431.6224.44
PB Ratio
8.516.195.123.326.944.04
P/TBV Ratio
9.436.565.253.367.084.08
P/FCF Ratio
---75.58--
P/OCF Ratio
---53.41--
EV/Sales Ratio
6.157.1016.0816.0529.2120.22
EV/FCF Ratio
-4.85--72.90--
Debt / Equity Ratio
1.340.770.040.040.080.03
Debt / FCF Ratio
---0.84--
Asset Turnover
0.280.260.150.190.140.15
Inventory Turnover
10.0211.779.069.377.565.37
Quick Ratio
2.162.343.828.092.765.00
Current Ratio
2.272.523.998.212.885.10
Return on Equity (ROE)
-95.34%-55.24%-30.55%-33.20%-41.08%-18.41%
Return on Assets (ROA)
-23.11%-19.50%-13.86%-12.34%-18.80%-9.31%
Return on Invested Capital (ROIC)
-45.46%-380.19%-67.32%-40.89%-101.00%-55.95%
Return on Capital Employed (ROCE)
-66.30%-45.00%-29.20%-16.20%-41.00%-13.60%
Earnings Yield
-19.59%-12.52%-6.93%-7.36%-7.06%-3.51%
FCF Yield
-19.21%-15.21%-7.00%1.32%-6.33%-4.96%
Buyback Yield / Dilution
0.00%-0.97%-24.75%--9.48%-4.98%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.